236 related articles for article (PubMed ID: 37183672)
1. An update on current and emerging drug treatments for idiopathic pulmonary fibrosis.
Trachalaki A; Sultana N; Wells AU
Expert Opin Pharmacother; 2023; 24(10):1125-1142. PubMed ID: 37183672
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological management of Idiopathic Pulmonary Fibrosis: current and emerging options.
Trachalaki A; Irfan M; Wells AU
Expert Opin Pharmacother; 2021 Feb; 22(2):191-204. PubMed ID: 32993388
[TBL] [Abstract][Full Text] [Related]
3. Switching antifibrotics in patients with idiopathic pulmonary fibrosis: a multi-center retrospective cohort study.
Suzuki Y; Mori K; Aono Y; Kono M; Hasegawa H; Yokomura K; Naoi H; Hozumi H; Karayama M; Furuhashi K; Enomoto N; Fujisawa T; Nakamura Y; Inui N; Nakamura H; Suda T
BMC Pulm Med; 2021 Jul; 21(1):221. PubMed ID: 34247593
[TBL] [Abstract][Full Text] [Related]
4. Treatment of idiopathic pulmonary fibrosis with Nintedanib: an update.
Wongkarnjana A; Yanagihara T; Kolb MR
Expert Rev Respir Med; 2019 Dec; 13(12):1139-1146. PubMed ID: 31564185
[No Abstract] [Full Text] [Related]
5. Current and Future Treatment Landscape for Idiopathic Pulmonary Fibrosis.
Bonella F; Spagnolo P; Ryerson C
Drugs; 2023 Nov; 83(17):1581-1593. PubMed ID: 37882943
[TBL] [Abstract][Full Text] [Related]
6. Unmet needs in the treatment of idiopathic pulmonary fibrosis-insights from patient chart review in five European countries.
Maher TM; Molina-Molina M; Russell AM; Bonella F; Jouneau S; Ripamonti E; Axmann J; Vancheri C
BMC Pulm Med; 2017 Sep; 17(1):124. PubMed ID: 28915874
[TBL] [Abstract][Full Text] [Related]
7. Real-World Study Analysing Progression and Survival of Patients with Idiopathic Pulmonary Fibrosis with Preserved Lung Function on Antifibrotic Treatment.
Noor S; Nawaz S; Chaudhuri N
Adv Ther; 2021 Jan; 38(1):268-277. PubMed ID: 33098554
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis.
Finnerty JP; Ponnuswamy A; Dutta P; Abdelaziz A; Kamil H
BMC Pulm Med; 2021 Dec; 21(1):411. PubMed ID: 34895203
[TBL] [Abstract][Full Text] [Related]
9. Shedding light on developmental drugs for idiopathic pulmonary fibrosis.
Spagnolo P; Bonella F; Ryerson CJ; Tzouvelekis A; Maher TM
Expert Opin Investig Drugs; 2020 Aug; 29(8):797-808. PubMed ID: 32538186
[TBL] [Abstract][Full Text] [Related]
10. Idiopathic Pulmonary Fibrosis for Cardiologists: Differential Diagnosis, Cardiovascular Comorbidities, and Patient Management.
van Cleemput J; Sonaglioni A; Wuyts WA; Bengus M; Stauffer JL; Harari S
Adv Ther; 2019 Feb; 36(2):298-317. PubMed ID: 30554332
[TBL] [Abstract][Full Text] [Related]
11. An update on emerging drugs for the treatment of idiopathic pulmonary fibrosis: a look towards 2023 and beyond.
Sofia C; Comes A; Sgalla G; Richeldi L
Expert Opin Emerg Drugs; 2023 Dec; 28(4):283-296. PubMed ID: 37953604
[TBL] [Abstract][Full Text] [Related]
12. Absence of early metabolic response assessed by 18F-FDG PET/CT after initiation of antifibrotic drugs in IPF patients.
Bondue B; Castiaux A; Van Simaeys G; Mathey C; Sherer F; Egrise D; Lacroix S; Huaux F; Doumont G; Goldman S
Respir Res; 2019 Jan; 20(1):10. PubMed ID: 30646908
[TBL] [Abstract][Full Text] [Related]
13. An update on emerging drugs for the treatment of idiopathic pulmonary fibrosis.
Aryal S; Nathan SD
Expert Opin Emerg Drugs; 2018 Jun; 23(2):159-172. PubMed ID: 29718783
[TBL] [Abstract][Full Text] [Related]
14. Management of Idiopathic Pulmonary Fibrosis.
Pleasants R; Tighe RM
Ann Pharmacother; 2019 Dec; 53(12):1238-1248. PubMed ID: 31280590
[No Abstract] [Full Text] [Related]
15. Differential Discontinuation Profiles between Pirfenidone and Nintedanib in Patients with Idiopathic Pulmonary Fibrosis.
Takehara K; Koga Y; Hachisu Y; Utsugi M; Sawada Y; Saito Y; Yoshimi S; Yatomi M; Shin Y; Wakamatsu I; Umetsu K; Kouno S; Nakagawa J; Sunaga N; Maeno T; Hisada T
Cells; 2022 Jan; 11(1):. PubMed ID: 35011705
[TBL] [Abstract][Full Text] [Related]
16. Treatment of idiopathic pulmonary fibrosis: an update on emerging drugs in phase II & III clinical trials.
MacIsaac S; Somboonviboon D; Scallan C; Kolb M
Expert Opin Emerg Drugs; 2024 Jun; 29(2):177-186. PubMed ID: 38588523
[TBL] [Abstract][Full Text] [Related]
17. Repurposing Anticancer Drugs for the Treatment of Idiopathic Pulmonary Fibrosis and Antifibrotic Drugs for the Treatment of Cancer: State of the Art.
Paliogiannis P; Fois SS; Fois AG; Cossu A; Palmieri G; Pintus G
Curr Med Chem; 2021; 28(11):2234-2247. PubMed ID: 32748739
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic targets in idiopathic pulmonary fibrosis.
Kolb M; Bonella F; Wollin L
Respir Med; 2017 Oct; 131():49-57. PubMed ID: 28947042
[TBL] [Abstract][Full Text] [Related]
19. Idiopathic pulmonary fibrosis in the era of antifibrotic therapy: Searching for new opportunities grounded in evidence.
Robalo-Cordeiro C; Campos P; Carvalho L; Borba A; Clemente S; Freitas S; Furtado S; Jesus JM; Leal C; Marques A; Melo N; Souto-Moura C; Neves S; Sousa V; Santos A; Morais A
Rev Port Pneumol (2006); 2017; 23(5):287-293. PubMed ID: 28668400
[TBL] [Abstract][Full Text] [Related]
20. Idiopathic Pulmonary Fibrosis: Where do We Stand and How Far to Go?
Singh V; Ulasov I; Gupta S; Singh A; Roy VK; Kharwar RK
Discov Med; 2024 Jan; 36(180):22-47. PubMed ID: 38273744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
